
Erlosam 150mg Tablet
Marketer
Samarth Life Sciences Pvt Ltd
Salt Composition
Erlotinib (150mg)
Overview Erlosam 150mg Tablet
Erlosam 150mg tablets treat non-small cell lung and pancreatic cancers. Administer this medication on an empty stomach, or at least one hour before or two hours after eating. Continue treatment as directed by your physician; duration depends on individual response. Follow your doctor's instructions precisely; incorrect usage or overdose may cause severe adverse effects. Therapeutic benefits might not appear for weeks or months; do not discontinue unless instructed. Common side effects include nausea, vomiting, tiredness, skin rashes, and weight loss. Severe diarrhea necessitates increased fluid intake or medical consultation. Photosensitivity may occur, so wear protective clothing and sunscreen outdoors. Report mouth sores, vision changes, or breathing problems immediately. Your doctor may order regular liver function tests. Inform your healthcare provider of all other medications you are taking, as interactions are possible. This medication is contraindicated during pregnancy and breastfeeding; effective contraception is crucial for both partners. Smoking cessation is strongly advised to optimize treatment efficacy. If using antacids or other medications, maintain a two-hour interval from Erlosam 150mg tablet ingestion.
Uses of Erlosam 150mg Tablet
Cancers of the pancreas and non-small-cell lung
Major Benefits of Erlosam 150mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the entire tablet; avoid chewing, crushing, or fracturing it. The Erlosam 150mg Tablet should be administered on an empty stomach.
Common Side effects of Erlosam 150mg Tablet:
- Abdominal pain
- Bone pain
- Breathlessness
- Constipation
- Cough
- Diarrhea
- Fatigue
- Fever
- Infection
- Muscle pain
- Nausea
- Rash
- Stomatitis (Inflammation of the mouth)
- Vomiting
- Weight loss
How to use Erlosam 150mg Tablet:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the entire tablet without chewing, crushing, or fracturing it. The Erlosam 150mg Tablet should be taken on an empty stomach.
How Erlosam 150mg Tablet works:
Erlosam 150mg tablets combat lung cancer by targeting epidermal growth factor receptors (EGFR). These receptors, present on the surface of lung cancer cells, regulate their growth. The drug's mechanism involves binding to EGFR, thereby blocking the cancer-promoting signals these receptors transmit, and consequently halting tumor expansion.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
The safety of alcohol consumption while taking Erlosam 150mg Tablet is undetermined. Seek medical advice.
PregnancyCONSULT YOUR DOCTOR
Using Erlosam 150mg tablets during pregnancy poses a confirmed risk to the fetus and is therefore inadvisable. Exceptions may exist in critical circumstances where a physician deems the potential benefits outweigh the inherent dangers. Always seek medical advice before use.
Breast feedingCONSULT YOUR DOCTOR
Use of Erlosam 150mg tablets while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingCONSULT YOUR DOCTOR
Driving ability while taking Erlosam 150mg Tablets is undetermined. Refrain from driving if concentration or reaction time is impaired.
KidneySAFE IF PRESCRIBED
Patients with kidney disease can generally use Erlosam 150mg tablets without dose modification. However, Erlosam 150mg tablets are contraindicated in individuals with severe kidney impairment.
LiverCAUTION
Patients with hepatic impairment should exercise caution when using Erlosam 150mg tablets; dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Erlosam 150mg Tablet :
Omit any missed Erlosam 150mg Tablet dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Erlosam 150mg Tablet
| Label | Value |
|---|---|
| Chemical Category | Quinazoline-based compound |
| Developing Habits | No. |
| Treatment Category | Cancer Medications |
